Prelude Capital Management, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $96,105 - $121,876	10,738 New	10,738 $103,000
Q1 2020 May 15, 2020	SELL	$5.8 - $18.56 $1,067 - $3,415	-184 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.31 - $17.81 $1,897 - $3,277	184 New	184 $3,000
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $800 - $1,495	-69 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$18.44 - $30.89 $11,580 - $19,398	-628 Reduced 90.1%	69 $2,000
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $1,651 - $3,110	100 Added 16.75%	697 $20,000
Q4 2018 Feb 14, 2019	SELL	$16.21 - $24.06 $956 - $1,419	-59 Reduced 8.99%	597 $12,000
Q3 2018 Nov 14, 2018	SELL	$8.0 - $22.11 $3,024 - $8,357	-378 Reduced 36.56%	656 $15,000
Q2 2018 Aug 14, 2018	BUY	$7.79 - $9.84 $5,717 - $7,222	734 Added 244.67%	1,034 $8,000
Q1 2018 May 15, 2018	BUY	$9.22 - $12.35 $2,766 - $3,705	300 New	300 $3,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $193M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.